Programmed Death-1 (PD-1; CD279) is an inhibitory receptor induced in activated T cells.
PD-1 engagement by its ligands, PD-L1 and PD-L2, maintains peripheral tolerance but also …

PD1 was originally discovered in 1992 as a molecule associated with activation-induced cell
death in T cells. Over the past 30 years, it was found that PD1 has a critical role in avoiding …

To explore the biology of lung adenocarcinoma (LUAD) and identify new therapeutic
opportunities, we performed comprehensive proteogenomic characterization of 110 tumors …

Sex bias exists in the development and progression of nonreproductive organ cancers, but
the underlying mechanisms are enigmatic. Studies so far have focused largely on sexual …

To prevent the destruction of tissues owing to excessive and/or inappropriate immune
responses, immune cells are under strict check by various regulatory mechanisms at …

PURPOSE KEYNOTE-158 (ClinicalTrials. gov identifier: NCT02628067) is a phase II basket
study investigating the antitumor activity and safety of pembrolizumab in multiple cancer …

The near-infrared-IIb (NIR-IIb)(1,500–1,700 nm) window is ideal for deep-tissue optical
imaging in mammals, but lacks bright and biocompatible probes. Here, we developed …

Checkpoint inhibitors have revolutionized cancer treatment. However, only a minority of
patients respond to these immunotherapies. Here, we report that blocking the inhibitory …

Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in a wide
variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells …

Summary Lymphocyte activation gene-3 (LAG-3) is a potent inhibitory co-receptor; yet, its
functional ligand remains elusive, with distinct potential ligands identified. Here, we …